ARTICLE | Finance
How Goldman Sachs’ life sciences strategy aims to scale private biotechs
Recent investment in Alterome is one of six since 2022 intended to allow biotechs to reach milestones while staying private longer
April 10, 2024 11:23 PM UTC
Editor in Chief Simone Fishburn selected this story as one of BioCentury's Best of 2024. To see the full list, click here.
Goldman Sachs’ investment in oncology company Alterome is the latest new deal from a strategy intended to position the firm’s portfolio companies to scale while still private, navigating a changing environment for biotechs as public markets’ expectations evolve...